Shasqi, Inc.
Publicly observedSan Francisco, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | San Francisco | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Shasqi, Inc. | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | ZDH5UZ2858G3 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant25 Sept 2025Publicly observed
NIH SBIR/STTR award: CEACAM5-targeted activation of potent chemotherapeutics via bioorthogonal click chemistry
USD 1,142,054.00 · National Cancer Institute · Source: NIH RePORTER (opens in a new tab)
- Grant25 Sept 2025Publicly observed
NIH SBIR/STTR award: CEACAM5-targeted activation of potent chemotherapeutics via bioorthogonal click chemistry
USD 1,094,189.00 · National Cancer Institute · Source: NIH RePORTER (opens in a new tab)
- Grant6 Sept 2024Publicly observed
NIH SBIR/STTR award: Antigen-targeted activation of Topo1 inhibitors via click chemistry
USD 431,859.00 · National Cancer Institute · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.